Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more

Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more

Pediatric cancers have unique genetic vulnerabilities

Most cancer drugs that target specific genetic mutations are designed for adult cancers rather than those in children, partly because pediatric cancers have fewer mutations. To look for more ways to target childhood cancers, researchers at the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and Boston Children’s Hospital decided to look for genetic dependencies in various pediatric cancers. […]

Read more

Blood test picks out cancers likely to benefit from targeted drugs

A simple and inexpensive blood test could pick out patients with stomach or oesophageal cancer who are likely to benefit from targeted treatment, a new study shows. The test, known as a liquid biopsy, detects cancer DNA in the bloodstream to reveal if stomach and oesophageal cancers are being driven by the presence of too many copies of a gene […]

Read more

Many Male Breast Cancers Diagnosed Late, and Delays Can Be Lethal

THURSDAY, Oct. 15, 2020 — Breast cancer in men is rare. But because it’s not often suspected in men, diagnosis often comes only after a tumor has begun to spread throughout the body, new research shows. “Approximately one-half of males with breast cancer received a diagnosis after it had already spread,” either to nearby or distant tissues, said a team […]

Read more

Immune system could be trained to spot drug-resistant cancers

Aggressive cancers could be treated with immunotherapies that direct the immune system to kill cancer cells with specific drug resistance-causing mutations, a major new study suggests. Drug resistance mutations which restore activity of the BRCA1 or BRCA2 genes as a way of avoiding the effects of drug treatment could leave tumors vulnerable to the effects of immunotherapy, the research found. […]

Read more

Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers

A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the […]

Read more

Botanical drug is shown to help patients with head and neck cancers

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. APG-157 is made up of multiple compounds produced by plants, including curcumin. UCLA Jonsson Comprehensive Cancer Center researchers found that treatment with this botanical drug resulted in […]

Read more

Researchers ID risks for second childhood cancers

Chemotherapy and radiation treatments have helped children survive cancer. Now University of Minnesota researchers are trying to find the ideal combinations that prevent the disease from coming back. Comparing outcomes for 22,000 survivors, the researchers found, as expected, that children treated with tumor-killing radiation were at elevated risks of second cancers. But they also discovered that certain chemo drugs increased […]

Read more

Laboratory studies identify a potential way to treat human cancers with ARID1A mutations

A new study shows that tumor cells depleted of ARID1A—a protein that acts as a cancer suppressor—become highly sensitive to anticancer poly ADP ribose polymerase (PARP) inhibitor drugs after radiation treatment. The research, led by Johns Hopkins Kimmel Cancer Center researchers, could advance efforts to treat many human cancers with loss of ARID1A that are resistant to current standard treatments, […]

Read more
1 2